scholarly article | Q13442814 |
P50 | author | Konstantinos Stravodimos | Q118869094 |
Manousos Makridakis | Q118869345 | ||
Antonia Vlahou | Q44903968 | ||
Jerome Zoidakis | Q52729662 | ||
Vasiliki Lygirou | Q59693741 | ||
Maria Frantzi | Q61793606 | ||
Harald Mischak | Q37828676 | ||
P2093 | author name string | Walter Kolch | |
Agnieszka Latosinska | |||
Axel S Merseburger | |||
Ioannis Katafigiotis | |||
William Mullen | |||
Maria G Roubelakis | |||
Marie C Hupe | |||
Maciej Dobrzynski | |||
Marika Mokou | |||
P2860 | cites work | Proteomic-based approach for biomarkers discovery in early detection of invasive urothelial carcinoma | Q82775285 |
Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinoma | Q83254150 | ||
Bladder cancer | Q84058686 | ||
The role of actinin-4 in bladder cancer invasion | Q84998833 | ||
On Molecular Classification of Bladder Cancer: Out of One, Many | Q85657356 | ||
eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation | Q87459522 | ||
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 | Q87711943 | ||
The star chart to Ta bladder cancer: an unsophisticated analysis of two-dimensional gel electrophoresis proteome maps | Q39911414 | ||
Cell surface associated alpha-L-fucose moieties modulate human breast cancer neoplastic progression | Q39972461 | ||
Brox, a novel farnesylated Bro1 domain-containing protein that associates with charged multivesicular body protein 4 (CHMP4). | Q40026149 | ||
Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer | Q40224310 | ||
Subsequent activation of mitogen-activated protein kinase after adhesion of transitional cell cancer cells to fibronectin | Q40709713 | ||
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. | Q40828142 | ||
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. | Q40912134 | ||
Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes | Q41747556 | ||
Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression | Q42136215 | ||
Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma | Q44824913 | ||
Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer | Q45224467 | ||
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. | Q53177490 | ||
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. | Q54391399 | ||
Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics | Q57712052 | ||
Platelet-Rich Plasma (PRP) Promotes Fetal Mesenchymal Stem/Stromal Cell Migration and Wound Healing Process | Q61281064 | ||
Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder | Q73504286 | ||
Significance of the Grb2 and son of sevenless (Sos) proteins in human bladder cancer cell lines | Q74336602 | ||
Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice | Q80084116 | ||
rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein | Q24316714 | ||
Signaling by target of rapamycin proteins in cell growth control | Q24522447 | ||
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling | Q24672005 | ||
The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death | Q26738549 | ||
The 26S proteasome is a multifaceted target for anti-cancer therapies | Q26795764 | ||
Cancer treatment and survivorship statistics, 2012 | Q27020961 | ||
Structure of the Bro1 Domain Protein BROX and Functional Analyses of the ALIX Bro1 Domain in HIV-1 Budding | Q27676148 | ||
Two Distinct Binding Modes Define the Interaction of Brox with the C-Terminal Tails of CHMP5 and CHMP4B | Q27678375 | ||
Global cancer statistics, 2012 | Q27860501 | ||
An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database | Q27861106 | ||
Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma | Q28084715 | ||
Regulation of translation initiation in eukaryotes: mechanisms and biological targets | Q28111696 | ||
eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation | Q28118876 | ||
A statistical model for identifying proteins by tandem mass spectrometry | Q28186251 | ||
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search | Q28211385 | ||
Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 | ||
Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis | Q28547700 | ||
The mechanism of eukaryotic translation initiation and principles of its regulation | Q29547270 | ||
UniProt: a hub for protein information | Q29547457 | ||
STRING v9.1: protein-protein interaction networks, with increased coverage and integration | Q29614691 | ||
TANDEM: matching proteins with tandem mass spectra | Q29615238 | ||
Molecular mechanisms of mTOR-mediated translational control | Q29615529 | ||
Universal sample preparation method for proteome analysis | Q29615662 | ||
A third-generation lentivirus vector with a conditional packaging system | Q29616120 | ||
A place for precision medicine in bladder cancer: targeting the FGFRs | Q30249143 | ||
Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization | Q30416020 | ||
A uniform proteomics MS/MS analysis platform utilizing open XML file formats | Q30478423 | ||
A guided tour of the Trans-Proteomic Pipeline | Q30497827 | ||
Network Biomarkers of Bladder Cancer Based on a Genome-Wide Genetic and Epigenetic Network Derived from Next-Generation Sequencing Data | Q31066313 | ||
Retracted: Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells | Q31078386 | ||
Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis | Q33231138 | ||
Differences in shotgun protein expression profile between superficial bladder transitional cell carcinoma and normal urothelium | Q33372054 | ||
The APEX Quantitative Proteomics Tool: generating protein quantitation estimates from LC-MS/MS proteomics results | Q33391589 | ||
Analysis of secreted proteins for the study of bladder cancer cell aggressiveness | Q33566081 | ||
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy | Q33572016 | ||
Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression | Q33703804 | ||
The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin | Q33882569 | ||
High-quality protein knowledge resource: SWISS-PROT and TrEMBL. | Q33961356 | ||
Proteomic tissue profiling for the improvement of grading of noninvasive papillary urothelial neoplasia | Q34045768 | ||
The cancerous translation apparatus | Q34182649 | ||
Biomarker research and some deduction in superficial bladder cancer cells combined with corresponding stroma | Q34202242 | ||
Stromal proteome expression profile and muscle-invasive bladder cancer research | Q34392967 | ||
The role of eIF3 and its individual subunits in cancer | Q34450907 | ||
eIF3: a versatile scaffold for translation initiation complexes | Q34558903 | ||
Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stroma | Q34616387 | ||
COMPASS: a suite of pre- and post-search proteomics software tools for OMSSA | Q34629832 | ||
Lentivirus-mediated knockdown of eukaryotic translation initiation factor 3 subunit D inhibits proliferation of HCT116 colon cancer cells | Q34706800 | ||
Protein interactome of muscle invasive bladder cancer | Q34876528 | ||
P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor model | Q35089340 | ||
Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study | Q35151995 | ||
The emerging importance of α-L-fucose in human breast cancer: a review. | Q35172546 | ||
Far from resolved: stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneity | Q35210941 | ||
Heterogeneity research in muscle-invasive bladder cancer based on differential protein expression analysis | Q35217663 | ||
The GOA database: gene Ontology annotation updates for 2015 | Q35253738 | ||
Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling | Q35266398 | ||
Low ANXA10 expression is associated with disease aggressiveness in bladder cancer | Q35620687 | ||
The 26S proteasome complex: an attractive target for cancer therapy | Q35624079 | ||
Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer | Q39062692 | ||
Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory | Q39334049 | ||
Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps | Q39404529 | ||
hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas | Q39459212 | ||
Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: a novel approach for the treatment of bladder cancer. | Q39460127 | ||
Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder | Q39613540 | ||
A molecular taxonomy for urothelial carcinoma. | Q39621985 | ||
High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. | Q39624174 | ||
The role of mTOR in bladder cancer | Q39769116 | ||
Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer | Q35665449 | ||
Knockdown of eIF3D inhibits breast cancer cell proliferation and invasion through suppressing the Wnt/β-catenin signaling pathway | Q36261389 | ||
Translational control in cancer etiology | Q36555212 | ||
The mTOR pathway in the control of protein synthesis | Q36600753 | ||
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting | Q37053995 | ||
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer | Q37122307 | ||
Alterations in human breast cancer adhesion-motility in response to changes in cell surface glycoproteins displaying alpha-L-fucose moieties. | Q37164814 | ||
Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer | Q37269864 | ||
Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models | Q37688606 | ||
Translational control in cancer. | Q37717999 | ||
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder | Q37730596 | ||
Urothelial carcinoma of the bladder: definition, treatment and future efforts | Q37944437 | ||
AMPK and mTOR in cellular energy homeostasis and drug targets | Q37948152 | ||
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? | Q37967115 | ||
Translation factors and ribosomal proteins control tumor onset and progression: how? | Q38104237 | ||
Eukaryotic translation initiation factors in cancer development and progression | Q38119725 | ||
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity | Q38297729 | ||
Alpha-L-fucose: a potentially critical molecule in pathologic processes including neoplasia | Q38332755 | ||
Targeting the translation machinery in cancer | Q38368049 | ||
Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer | Q38452601 | ||
Developing proteomic biomarkers for bladder cancer: towards clinical application | Q38511509 | ||
mTOR inhibitors in urinary bladder cancer. | Q38737064 | ||
Immunotherapy: a new treatment paradigm in bladder cancer | Q38743589 | ||
Origins of Bladder Cancer | Q38747183 | ||
EIF3D silencing suppresses renal cell carcinoma tumorigenesis via inducing G2/M arrest through downregulation of Cyclin B1/CDK1 signaling | Q38781713 | ||
The oncogenic role of EIF3D is associated with increased cell cycle progression and motility in prostate cancer | Q38868194 | ||
Knockdown of eIF3d inhibits cell proliferation through G2/M phase arrest in non-small cell lung cancer | Q38871165 | ||
RNAi-Mediated Silencing of EIF3D Alleviates Proliferation and Migration of Glioma U251 and U87MG Cells | Q38909542 | ||
Knockdown of EIF3D suppresses proliferation of human melanoma cells through G2/M phase arrest | Q38947243 | ||
Emerging role of mTOR in the response to cancer therapeutics | Q38964435 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 41 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | tumor invasion | Q60750433 |
P304 | page(s) | 69435-69455 | |
P577 | publication date | 2017-04-20 | |
P1433 | published in | Oncotarget | Q1573155 |
P1476 | title | Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention | |
P478 | volume | 8 |